Lifeward (LFWD) Stock Overview
A medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LFWD Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lifeward Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.98 |
| 52 Week High | US$15.24 |
| 52 Week Low | US$4.14 |
| Beta | 0.33 |
| 1 Month Change | -5.42% |
| 3 Month Change | 15.95% |
| 1 Year Change | -53.09% |
| 3 Year Change | -85.93% |
| 5 Year Change | -95.48% |
| Change since IPO | -99.90% |
Recent News & Updates
Narrative Update • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.
Narrative Update • Apr 30
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions related to fair value, discount rate, revenue growth, profit margin and future P/E estimates. Analyst Commentary Bearish analysts describe the move to a US$10 price target as a recalibration rather than a clear vote of confidence, pointing out that the new target still reflects uncertainty around how Lifeward can deliver on the assumptions used in updated fair value work.Recent updates
Narrative Update • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.Narrative Update • Apr 30
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions related to fair value, discount rate, revenue growth, profit margin and future P/E estimates. Analyst Commentary Bearish analysts describe the move to a US$10 price target as a recalibration rather than a clear vote of confidence, pointing out that the new target still reflects uncertainty around how Lifeward can deliver on the assumptions used in updated fair value work.
Narrative Update • Apr 15
LFWD: Higher Risk Reward View Will Support Future Upside Potential
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that together change their view of the company’s balance of risk and reward. Analyst Commentary Bullish analysts are framing the new US$10 price target as a reassessment of Lifeward’s potential risk and reward, rather than just a reaction to short term news.Narrative Update • Mar 31
LFWD: Higher Fair Value Assumptions Will Support Future Cash Flow
Analysts have lifted the price target for Lifeward to $10 from $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Analysts lifting the Lifeward price target to $10 from $4.50 are updating their view of what they see as fair value, based on refreshed assumptions for revenue growth, profitability, discount rates, and future P/E levels.Narrative Update • Mar 17
LFWD: Reverse Split And Convertible Notes Will Support Future Upside
Analysts have raised their price target on Lifeward from $10.00 to about $120.00, citing updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Lifeward plans dedicated clinic days with Shirley Ryan AbilityLab in Chicago starting in the second quarter of 2026, focused on evaluation and access to the FDA cleared ReWalk Personal Exoskeleton for people with spinal cord injury (Key Developments).Narrative Update • Mar 03
LFWD: Reverse Split And New Financing Will Support Future Cash Flow
Analysts have lifted their price target for Lifeward to $87.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin, and a lower future P/E multiple. What's in the News Lifeward plans a 1 for 12 reverse split of its ordinary shares, effective at the open of trading on February 24, 2026.Narrative Update • Feb 17
LFWD: Convertible Notes And Share Actions Will Drive Future P E Repricing
Analysts have modestly adjusted their price target on Lifeward, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that slightly refine their view of the company’s risk and earnings power in dollar terms. What's in the News Lifeward plans a Special and Extraordinary Shareholders Meeting on March 12, 2026 at its Hudson, Massachusetts offices to address corporate matters previously approved in principle at earlier meetings (company event filing).Narrative Update • Feb 03
LFWD: New Convertible Funding And Reverse Split Will Support Future Upside
Narrative Update on Lifeward Analysts have slightly reduced their price target for Lifeward, citing small adjustments to the discount rate and future P/E assumptions, along with modest changes to expected revenue growth and profit margins. What's in the News Lifeward completed a private placement on November 14, 2025, issuing secured convertible promissory notes with an aggregate principal of $3,000,000, carrying 15% annual interest and convertible into ordinary shares at $0.45 per share, with participation from Oramed Ltd and maturity on May 14, 2026 (Key Developments).Narrative Update • Jan 20
LFWD: Future P/E Repricing Will Rely On Successful Convertible Note Execution
Analysts have raised their price target for Lifeward to reflect higher modelled revenue growth of about 53% and a very large future P/E multiple, even as they factor in a lower profit margin and a slightly higher discount rate. What's in the News Lifeward entered into a private placement agreement to issue Senior Secured Convertible Notes with a principal amount of $20,000,000 and accompanying warrants, with the notes initially convertible at $0.45 per share and accruing 8.0% annual interest that may rise to 15.0% in the event of default (Key Developments).Narrative Update • Jan 06
LFWD: Reverse Split And New Funding Will Set Up Future Upside
Analysts have reduced their fair value estimate for Lifeward from US$13.00 to US$10.00. They attribute this change to more conservative assumptions on revenue growth, profit margins and the P/E multiple they apply to the company.Narrative Update • Dec 17
LFWD: Improved Capital Structure Will Support Future Cash Flow Potential
Analysts have nudged their price target for Lifeward slightly higher to reflect marginally lower perceived risk and modest improvements in long term profitability and valuation assumptions, even as their underlying fair value estimate remains anchored around $5.17 per share. What's in the News Lifeward completed a $3 million private placement via secured convertible promissory notes bearing 15% interest, convertible at $0.45 per share and maturing May 14, 2026, with participation from Oramed Ltd.Narrative Update • Dec 03
LFWD: Improved Medicare Reimbursement Trends Will Support Future Cash Flow
Narrative Update on Lifeward The analyst price target for Lifeward has been revised upward to approximately 5.17 dollars per share from 5.17 dollars previously. This reflects analysts' expectations for faster revenue growth, improved profit margins, and a lower future price to earnings multiple.Narrative Update • Nov 19
LFWD: Rising Medicare Approvals And New Funding Will Support Revenue Outlook
Analysts have significantly lowered their price target for Lifeward from $8.00 to approximately $5.17. They cite more conservative revenue growth projections and a notable reduction in expected profit margins.Analysis Article • Sep 25
Even With A 27% Surge, Cautious Investors Are Not Rewarding Lifeward Ltd.'s (NASDAQ:LFWD) Performance Completely
Despite an already strong run, Lifeward Ltd. ( NASDAQ:LFWD ) shares have been powering on, with a gain of 27% in the...Narrative Update • Aug 16
FDA Clearance And Expanded Payer Channels Will Drive Advanced Mobility
The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable. What's in the News Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.Analysis Article • Jun 19
Many Still Looking Away From Lifeward Ltd. (NASDAQ:LFWD)
With a price-to-sales (or "P/S") ratio of 0.5x Lifeward Ltd. ( NASDAQ:LFWD ) may be sending very bullish signals at the...New Narrative • May 11
AlterG NEO And ReWalk 70 Will Shape Future Market Opportunities
Established lump sum payments and expanded into U.S. workers' compensation, creating stable revenue streams and improving net margins through efficient claim processing.Analysis Article • Feb 05
Market Cool On Lifeward Ltd.'s (NASDAQ:LFWD) Revenues Pushing Shares 50% Lower
Lifeward Ltd. ( NASDAQ:LFWD ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Oct 30
Not Many Are Piling Into Lifeward Ltd. (NASDAQ:LFWD) Stock Yet As It Plummets 25%
Unfortunately for some shareholders, the Lifeward Ltd. ( NASDAQ:LFWD ) share price has dived 25% in the last thirty...Analysis Article • Oct 15
Here's Why Lifeward (NASDAQ:LFWD) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • Aug 01
ReWalk Robotics Ltd. (NASDAQ:LFWD) Soars 26% But It's A Story Of Risk Vs Reward
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Analysis Article • May 30
Is ReWalk Robotics (NASDAQ:LFWD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysis Article • Mar 14
Investors Give ReWalk Robotics Ltd. (NASDAQ:LFWD) Shares A 28% Hiding
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shares have had a horrible month, losing 28% after a relatively good period...Shareholder Returns
| LFWD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 9.1% | 1.8% | 1.2% |
| 1Y | -53.1% | -17.9% | 28.7% |
Return vs Industry: LFWD underperformed the US Medical Equipment industry which returned -17.9% over the past year.
Return vs Market: LFWD underperformed the US Market which returned 28.7% over the past year.
Price Volatility
| LFWD volatility | |
|---|---|
| LFWD Average Weekly Movement | 9.6% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LFWD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LFWD's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 81 | William Grant | golifeward.com |
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals’ post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors.
Lifeward Ltd. Fundamentals Summary
| LFWD fundamental statistics | |
|---|---|
| Market cap | US$19.84m |
| Earnings (TTM) | -US$25.87m |
| Revenue (TTM) | US$20.92m |
0.9x
P/S Ratio-0.8x
P/E RatioIs LFWD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LFWD income statement (TTM) | |
|---|---|
| Revenue | US$20.92m |
| Cost of Revenue | US$13.28m |
| Gross Profit | US$7.65m |
| Other Expenses | US$33.52m |
| Earnings | -US$25.87m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.19 |
| Gross Margin | 36.55% |
| Net Profit Margin | -123.66% |
| Debt/Equity Ratio | 115.7% |
How did LFWD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/26 00:24 |
| End of Day Share Price | 2026/05/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lifeward Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Taylor | Barclays |
| William Plovanic | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |